 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
19 June 2001 | Volume 134 Issue 12 | Pages 1087-1095
Background: The validity and magnitude of an association between myositis and malignant disease continue to be debated. Such issues as the legitimacy of a myositis diagnosis and distinction among myositis subgroups in previous population-based studies remain unresolved.
Objective: To determine the risk for malignant disease in patients with biopsy-proven inflammatory myopathies.
Design: Population-based, retrospective cohort study.
Setting: Victoria, Australia.
Patients: 537 patients in whom a biopsy-positive idiopathic inflammatory myopathy was first diagnosed from 1981 through 1995.
Measurements: Standardized incidence ratios were calculated to compare the incidence of malignant disease in patients with inflammatory myopathy and the general population.
Results: A total of 116 cases of malignant disease were found in 104 patients. Seventy-four cases were identified concurrently with (within 7 days) or after diagnosis of myositis. The highest risk for malignant disease was associated with dermatomyositis (standardized incidence ratio, 6.2 [95% CI, 3.9 to 10.0]). The risk was also increased in polymyositis (standardized incidence ratio, 2.0 [CI, 1.4 to 2.7]), although the relative risk for malignant disease in dermatomyositis compared with polymyositis was 2.4 (CI, 1.3 to 4.2). An increased risk for malignant disease was also found in inclusion-body myositis (standardized incidence ratio, 2.4 [CI, 1.2 to 4.9]). The excess risk for malignant disease diminished with time (standardized incidence ratio, 4.4 [CI, 2.7 to 7.1] in the first year; 3.4 [CI, 2.3 to 5.1] between 1 and 3 years; 2.2 [CI, 1.3 to 3.9] between 3 and 5 years; and 1.6 [CI, 1.0 to 2.6] beyond 5 years [P for trend, 0.002]).
Conclusion: The risk for malignant disease is increased in biopsy-proven dermatomyositis and polymyositis and also appears to be increased in inclusion-body myositis.
Author and Article Information
From Cabrini Medical Centre, Malvern, and Monash University, Melbourne University, and Cancer Control Research Institute of the Anti-Cancer Council of Victoria, Melbourne, Australia.
Grant Support: By a grant from the Arthritis Foundation of Australia.
Requests for Single Reprints: Rachelle Buchbinder, MBBS (Hons), MSc, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144; e-mail, rachelle.buchbinder{at}med.monash.edu.au.
Current Author Addresses: Dr. Buchbinder: Department of Clinical Epidemiology, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.
Dr. Forbes: Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital Campus, Commercial Road, Prahran, Victoria, Australia 3181.
Dr. Hall: Suite 43, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.
Dr. Dennett: State Neuropathology Service, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia 3010.
Dr. Giles: Cancer Epidemiology Centre and Victorian Cancer Registry, Cancer Control Research Institute of the Anti-Cancer Council of Victoria, 100 Drummond Street, Carlton South, Victoria, Australia 3053.
Author Contributions: Conception and design: R. Buchbinder, A. Forbes, S. Hall.
Analysis and interpretation of the data: R. Buchbinder, A. Forbes.
Drafting of the article: R. Buchbinder, A. Forbes.
Critical revision of the article for important intellectual content: R. Buchbinder, A. Forbes, S. Hall, X. Dennett, G. Giles.
Final approval of the article: R. Buchbinder, X. Dennett, G. Giles.
Provision of study materials or patients: R. Buchbinder, X. Dennett, G. Giles.
Statistical expertise: A. Forbes.
Obtaining of funding: R. Buchbinder.
Administrative, technical, or logistic support: R. Buchbinder, G. Giles.
Collection and assembly of data: R. Buchbinder, X. Dennett, G. Giles. ARTICLE
Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  H. Gunawardena, L. R. Wedderburn, J. North, Z. Betteridge, J. Dunphy, H. Chinoy, J. E. Davidson, R. G. Cooper, N. J. McHugh, and for the Juvenile Dermatomyositis Research Group UK Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis Rheumatology, March 1, 2008; 47(3): 324 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chinoy, N. Fertig, C. V Oddis, W. E R Ollier, and R. G Cooper The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis Ann Rheum Dis, October 1, 2007; 66(10): 1345 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito, K. Komura, T. Matsushita, H. Orito, Y. Hamaguchi, K. Yanaba, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy Rheumatology, January 1, 2007; 46(1): 25 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Smedby, E. Baecklund, and J. Askling Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I M Bronner, M F G van der Meulen, M de Visser, S Kalmijn, W J van Venrooij, A E Voskuyl, H J Dinant, W H J P Linssen, J H J Wokke, and J E Hoogendijk Long-term outcome in polymyositis and dermatomyositis Ann Rheum Dis, November 1, 2006; 65(11): 1456 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gabrilovich, M. Raza, S. Dolan, and T. Raza Paraneoplastic Polymyositis Associated With Squamous Cell Carcinoma of the Lung Chest, June 1, 2006; 129(6): 1721 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Polisson, J. T. Crocker, P. R. Mueller, N. L. Harris, and L. M. Duncan Case 29-2005 - A 68-Year-Old Man with Periorbital Swelling, Rash, and Weakness N. Engl. J. Med., September 22, 2005; 353(12): 1275 - 1284. [Full Text] [PDF]
|
|
|
|
|
|
Z. Amoura, P. Duhaut, D. L. T. Huong, B. Wechsler, N. Costedoat-Chalumeau, C. Frances, P. Cacoub, T. Papo, S. Cormont, Y. Touitou, et al. Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1279 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Casciola-Rosen, K. Nagaraju, P. Plotz, K. Wang, S. Levine, E. Gabrielson, A. Corse, and A. Rosen Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy J. Exp. Med., February 22, 2005; 201(4): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mehta and V. S. Swaroop 70-Year-Old Woman With Rash and Muscle Weakness Mayo Clin. Proc., July 1, 2004; 79(7): 923 - 926. [PDF]
|
|
|
|
 |
|
 J. P. Callen When and How Should the Patient With Dermatomyositis or Amyopathic Dermatomyositis Be Assessed for Possible Cancer? Arch Dermatol, July 1, 2002; 138(7): 969 - 971. [Full Text] [PDF]
|
|
|
|
 |
|
 Malignancy and Dermatomyositis: A Neuropathologist's Perspective Journal Watch Dermatology, September 11, 2001; 2001(911): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Risk for Malignancy in Inflammatory Myopathies Still Uncertain Journal Watch Neurology, July 26, 2001; 2001(726): 6 - 6. [Full Text]
|
|
